

From: Diāna Arāja [<mailto:Diana.Araja@vm.gov.lv>]

Sent: Sunday, January 29, 2017 10:10 PM

To: SANTE HTA

Subject: Re: PUBLIC CONSULTATION: EU initiative for strengthening EU cooperation on Health Technology Assessment

Dear Colleagues,

In reply to your kind suggestion to send the comments outside the formal framework, I send some considerations.

The proposed centralisation of HTA can benefit for countries with huge capacity spent for HTA currently, if these countries are able to achieve the agreement on the leadership of this process. Countries with relatively few human and financial resources spent for HTA, can expect that the financial contributions requested from the MSs in case of centralisation will be higher than the financing of national HTA process in these countries. At the same time, the accelerated HTA reports are not so crucial in circumstances of the years-long waiting list for inclusion of new medicines in reimbursed list due to high prices and lack of budget allocated for them.

It seems that the process of centralisation can be applicable for all countries, if the centralised HTA process is followed by the centralised price setting with the price differentiation, for instance, based on social-economic indicators, such as GDP per capita in PPS. In this case the multiplied external price references and confidential agreements would lose the actuality, but parallel import should be cancelled for medicines as for strategic products with impact on the public health.

Kind regards,

Diāna Arāja

MoH, Department of Pharmacy

Latvia